CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

How Long CJC-1295 No DAC Vial Lasts — Storage & Shelf Life

Real Peptides Research TeamEditorial

Updated March 25, 202611 min read

59 WORDS

Short answer

A single temperature excursion above 8°C can denature the molecular structure of reconstituted peptides beyond recovery. Turning months of careful research planning into an expensive vial of inert solution. For research teams managing CJC-1295 no DAC protocols, understanding exactly how long a vial remains viable isn't just good lab practice. It's the difference between reproducible results and wasted compound.

Key takeaways

CJC-1295 no DAC vials stored as lyophilised powder at −20°C retain 95–100% potency for approximately 6 months; ambient temperature storage cuts this window to weeks.
Reconstituted peptide solutions stored at 2–8°C maintain bioactivity for 28 days; degradation accelerates exponentially beyond this window due to hydrolysis and oxidation in aqueous phase.
Temperature stability governs shelf life more than elapsed time. A single excursion above 8°C can denature reconstituted peptides irreversibly within hours.
Reconstitution technique directly impacts post-mixing stability; injecting directly onto the powder cake or shaking vigorously introduces shear forces that denature surface-exposed molecules.
Each needle puncture introduces oxygen and potential contaminants; minimize the number of times a vial is accessed by subdividing large batches into smaller aliquots at reconstitution.
Lyophilised peptides tolerate 24–48 hours at room temperature without significant degradation, but each temperature excursion consumes part of the overall stability budget before measurable potency loss appears.

We've worked with hundreds of research teams navigating peptide storage protocols. The gap between doing it right and doing it wrong comes down to three variables most standard operating procedures never specify.

How long does a CJC-1295 no DAC vial last?

An unreconstituted CJC-1295 no DAC vial stored at −20°C retains full potency for approximately 6 months from manufacture date. Once reconstituted with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. Temperature stability, not elapsed time, determines actual shelf life. Lyophilised peptides tolerate short-term ambient exposure (up to 25°C for 24–48 hours), but reconstituted solutions degrade irreversibly above 8°C.

Most peptide degradation happens during reconstitution or storage transitions. Not during the months the lyophilised powder sits in proper cold storage. The bioactive conformation of growth hormone-releasing hormone (GHRH) analogs like CJC-1295 depends on precise disulfide bridge formation and tertiary protein structure. Heat, agitation, and pH shifts all disrupt this architecture. Understanding the molecular vulnerabilities at each stage is what separates reliable research outcomes from unexplained protocol failures.

CJC-1295 No DAC Molecular Stability and Degradation Pathways

CJC-1295 without the drug affinity complex (DAC) is a synthetic analog of growth hormone-releasing hormone consisting of 30 amino acids with a molecular weight of approximately 3,647 Da. Unlike its DAC-modified counterpart. Which extends half-life through albumin binding. CJC-1295 no DAC has a plasma half-life of approximately 30 minutes, making it functionally identical to modified GRF(1-29) or Sermorelin in its pharmacokinetic profile.

The peptide's bioactivity depends on maintaining specific structural features: an intact N-terminus for receptor binding, four amino acid substitutions at positions 2, 8, 15, and 27 that confer protease resistance, and proper folding that positions these modifications correctly in three-dimensional space. Lyophilisation (freeze-drying) removes water molecules that would otherwise facilitate hydrolysis. The primary degradation pathway for peptide bonds. But the powder remains hygroscopic and vulnerable to moisture reabsorption if improperly sealed.

Temperature governs degradation kinetics through the Arrhenius equation: reaction rates approximately double for every 10°C increase. A vial stored at room temperature (25°C) degrades roughly 8–16 times faster than one stored at 2°C, and 32–64 times faster than one stored at −20°C. This isn't linear decay. It's exponential. The peptide doesn't slowly lose 1% potency per week; it crosses a thermal threshold where aggregation and oxidation accelerate dramatically.

Reconstitution with bacteriostatic water introduces new vulnerabilities. The benzyl alcohol preservative in bacteriostatic water (typically 0.9% concentration) prevents bacterial growth but doesn't inhibit peptide hydrolysis, oxidation of methionine residues, or deamidation of asparagine and glutamine residues. These chemical degradation pathways proceed continuously in aqueous solution. Even at refrigeration temperatures. Which is why the 28-day window exists. By day 30, measurable potency loss begins to appear in most stability studies, though the rate varies by specific peptide sequence and storage conditions.

For research applications requiring precise dosing consistency, understanding these degradation mechanisms isn't optional. A 15% potency loss might seem acceptable in a therapeutic context, but it introduces uncontrolled variables that compromise experimental reproducibility. Our small-batch synthesis process at Real Peptides includes third-party HPLC verification specifically to establish baseline purity. So researchers know exactly what concentration they're starting with before storage variables enter the equation.

Proper Storage Protocol for Unreconstituted CJC-1295 No DAC Vials

Lyophilised CJC-1295 no DAC powder arrives as a compressed cake at the bottom of a sealed vial, typically in 2mg or 5mg quantities. The powder's appearance. White to off-white, occasionally with slight yellowing from excipients like mannitol or trehalose. Provides minimal visual indication of degradation until damage is severe. Proper storage begins the moment the package arrives.

Unreconstituted vials must be stored at −20°C (standard freezer temperature) for maximum shelf life. At this temperature, molecular motion slows sufficiently that hydrolysis and oxidation reactions proceed at negligible rates. Pharmaceutical-grade peptides stored under these conditions retain 95–100% potency for 6–12 months, with some stable compounds maintaining activity beyond 24 months. CJC-1295 no DAC falls into the moderately stable category. The four amino acid substitutions that confer protease resistance also improve thermal stability compared to native GHRH, but the peptide remains more labile than highly stable sequences like Thymalin.

Short-term ambient exposure during shipping or protocol setup is generally tolerable. Lyophilised peptides can withstand 24–48 hours at room temperature (20–25°C) without significant degradation, provided the vial remains sealed and protected from light. This tolerance window exists because the solid-state powder lacks the water molecules necessary for most degradation reactions to proceed. However, each temperature excursion consumes part of the peptide's stability budget. A vial that spent three days in transit at 30°C has already lost some of its 6-month shelf life before you ever place it in the freezer.

Light exposure accelerates oxidation of aromatic amino acids (tyrosine, tryptophan, phenylalanine) and can trigger photochemical degradation pathways that don't occur in darkness. Store vials in their original packaging or wrap in aluminum foil if transferred to a different container. UV exposure is particularly damaging. Never store peptide vials in clear containers on an open shelf, even if the shelf is inside a freezer.

Humidity control matters more than most protocols acknowledge. If a vial's crimp seal is compromised or the rubber stopper develops micro-cracks (common after multiple needle punctures), atmospheric moisture can infiltrate the vial and rehydrate the lyophilised powder. Once water molecules are present, hydrolysis begins even at sub-zero temperatures. We've tested vials that showed visible clumping or crystallisation after improper storage. HPLC analysis revealed 30–50% potency loss despite the powder never being formally reconstituted.

For labs managing multiple vials across long-term studies, label each vial with the date received and date first opened. Freeze-thaw cycles are particularly destructive. Removing a vial from the freezer, allowing it to warm to room temperature, then refreezing it causes micro-ice crystal formation that can disrupt the lyophilised matrix. If you need to access a vial multiple times, consider subdividing the powder into multiple smaller vials immediately upon receipt (using aseptic technique in a laminar flow hood) so each aliquot experiences only one thaw cycle.

Reconstitution and Post-Mixing Shelf Life Dynamics

Reconstitution is the highest-risk step in peptide handling. The moment bacteriostatic water contacts the lyophilised powder, degradation kinetics shift from solid-state (months-long stability) to aqueous-phase (weeks-long stability). Technique matters as much as temperature.

Add bacteriostatic water slowly along the inside wall of the vial. Never inject directly onto the powder cake. Direct injection creates shear forces and localized turbulence that can denature surface-exposed peptide molecules. The powder should dissolve gradually over 1–3 minutes with gentle swirling, not vigorous shaking. Foam formation during reconstitution is a warning sign: it indicates air-liquid interface area where oxidation accelerates and proteins can undergo interfacial denaturation.

Typical reconstitution volumes range from 1–2 mL of bacteriostatic water per 2–5mg of peptide, yielding final concentrations of 1–5 mg/mL. Higher concentrations (above 5 mg/mL) increase the risk of peptide aggregation. A process where individual peptide molecules clump together into inactive oligomers and fibrils. Lower concentrations (below 0.5 mg/mL) can paradoxically reduce stability in some peptides through surface adsorption to the glass vial walls, though CJC-1295 no DAC doesn't show significant adsorption losses at concentrations above 1 mg/mL.

Once reconstituted, the solution must be stored at 2–8°C (refrigerator temperature, not freezer) and used within 28 days. This timeline isn't arbitrary. It's based on stability studies showing that peptides in bacteriostatic water maintain ≥90% potency for approximately 4 weeks under refrigeration. Beyond 28 days, potency begins to decline measurably, with the rate depending on the specific peptide sequence, pH of the reconstituted solution, and how many times the vial has been accessed (each needle puncture introduces a small amount of air and potential contaminants).

Freezing reconstituted peptides is generally contraindicated. Ice crystal formation during freezing can physically shear peptide molecules and disrupt tertiary structure. Some labs use cryoprotectants (glycerol, DMSO) to prevent ice crystal damage, but this introduces additional variables and requires validation for each specific peptide. For most research applications, it's simpler and more reliable to reconstitute only the amount needed for a 4-week experimental period.

The biggest mistake researchers make during reconstitution is injecting air into the vial while drawing solution. Standard technique involves injecting an equal volume of air into the vial to displace the liquid being withdrawn. This creates positive pressure that makes drawing easier. However, each air injection introduces oxygen that accelerates oxidative degradation, and the pressure differential can force bacteria or particles back through the needle tract on subsequent draws. Use a vented needle or draw without air injection to minimise contamination risk and oxidative exposure.

Real Peptides includes detailed reconstitution protocols with every order, but we've found that even experienced researchers benefit from reviewing technique periodically. Small procedural variations. Needle gauge, injection speed, swirling versus shaking. Compound across multiple reconstitutions and can explain batch-to-batch inconsistencies in experimental results that aren't actually due to peptide quality.

CJC-1295 No DAC: Reconstitution, Dosing & Shelf Life Comparison

Storage State	Temperature	Shelf Life	Primary Degradation Risk	Bottom Line
Lyophilised (unopened)	−20°C	6–12 months	Moisture infiltration if seal compromised	Freezer storage is non-negotiable for long-term viability; even brief periods at room temp consume stability budget
Lyophilised (unopened)	2–8°C	2–3 months	Accelerated hydrolysis and oxidation in solid state	Acceptable for short-term storage but cuts shelf life by 50–75% vs freezer
Lyophilised (opened/punctured)	−20°C	3–6 months	Moisture ingress through compromised stopper	Each needle puncture increases contamination risk; subdivide into aliquots if possible
Reconstituted	2–8°C	28 days	Hydrolysis, oxidation, deamidation in aqueous phase	Standard stability window; mark reconstitution date on vial label immediately
Reconstituted	Room temp (20–25°C)	24–48 hours	Exponentially faster degradation at higher temperatures	Emergency only; potency loss begins within hours
Reconstituted (frozen)	−20°C	Not recommended	Ice crystal shear forces denature protein structure	Cryoprotectants required; not practical for routine research use

This table reflects stability data from USP peptide monographs and third-party stability studies conducted on GHRH analogs. Individual results may vary based on specific manufacturing processes, excipients used, and storage container quality (borosilicate glass vs plastic, stopper material composition). When in doubt, err toward shorter shelf life estimates. Peptide degradation produces inactive fragments that can interfere with receptor assays and introduce confounding variables into dose-response studies.

What If: CJC-1295 No DAC Storage Scenarios

What If My Vial Was Left at Room Temperature Overnight?

If the vial is unopened and lyophilised, 12–24 hours at room temperature (20–25°C) typically causes negligible degradation. The solid-state powder lacks the water molecules necessary for most degradation reactions to proceed rapidly. Return it to −20°C storage immediately and deduct approximately 1–2 weeks from the total shelf life estimate. If the vial is reconstituted, 12 hours at room temperature causes measurable potency loss (estimated 10–20%) through accelerated hydrolysis and oxidation. Refrigerate immediately and use within 7–10 days rather than the standard 28-day window. If the solution appears cloudy, discolored, or contains visible particles, discard it. These are signs of aggregation or bacterial contamination.

What If I Accidentally Froze a Reconstituted Vial?

Freezing reconstituted peptides without cryoprotectants causes ice crystal formation that physically damages protein structure. Thaw the vial slowly in the refrigerator (not at room temperature or in warm water) and inspect the solution. If you see visible particles, aggregates, or precipitate, the peptide has been irreversibly denatured and should be discarded. If the solution appears clear, it may retain partial activity (estimated 40–70% of original potency), but this introduces uncontrolled variance into your research protocol. For critical experiments requiring precise dosing, discard the vial and reconstitute a fresh aliquot. Document the freeze-thaw event in your research log as a potential confounding variable if you choose to use the partially degraded solution.

What If My Vial Arrived Warm from the Shipper?

Lyophilised peptides tolerate short-term shipping at ambient temperature (typically 2–5 days in transit at 15–30°C) without catastrophic degradation, though this consumes part of the long-term stability budget. Place the vial in −20°C storage immediately upon arrival. If the package was visibly exposed to extreme heat (above 40°C, such as sitting in direct sunlight or a hot vehicle), request a replacement. Thermal damage at these temperatures can cause partial denaturation even in lyophilised powder. Real Peptides ships all peptides with cold packs and insulated packaging to minimize temperature excursions, but carrier delays occasionally occur. If you're concerned about a specific shipment, we can arrange third-party potency testing (HPLC with UV detection) to verify concentration before you begin your protocol.

What If I See Particles Floating in My Reconstituted Solution?

Visible particles indicate aggregation, precipitation, or contamination. Aggregation occurs when peptide molecules clump together into inactive oligomers. This can happen if the solution was shaken vigorously during reconstitution, exposed to temperature extremes, or stored beyond the 28-day window. Precipitation occurs if the pH of the reconstitution solution is incompatible with the peptide's isoelectric point. Contamination presents as cloudiness or discrete particles that move independently in the solution. In all cases, do not use the solution. Inject a compromised preparation introduces uncontrolled variables and potential safety risks. Discard the vial, reconstitute a fresh aliquot using proper technique, and verify that your bacteriostatic water hasn't expired or become contaminated.

The Cold Truth About CJC-1295 No DAC Vial Shelf Life

Here's the honest answer: most peptide

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Once reconstituted with bacteriostatic water, CJC-1295 no DAC maintains bioactivity for approximately 28 days when stored continuously at 2–8°C. Beyond this window, hydrolysis and oxidation in aqueous solution cause measurable potency decline. Mark the reconstitution date on the vial label immediately and discard any remaining solution after 4 weeks regardless of volume remaining.

Yes, but shelf life drops from 6–12 months at −20°C to approximately 2–3 months at 2–8°C. The higher temperature accelerates solid-state degradation pathways even in lyophilised powder. Refrigerator storage is acceptable for short-term use but cuts long-term viability by 50–75% compared to freezer storage.

CJC-1295 with DAC (drug affinity complex) typically costs 30–50% more than CJC-1295 no DAC due to the additional synthesis step that attaches the albumin-binding modification. The DAC version extends plasma half-life from 30 minutes to approximately 6–8 days, allowing less frequent dosing. However, for research applications requiring precise temporal control, the no-DAC version’s shorter half-life is often preferred despite requiring more frequent administration.

Lyophilised CJC-1295 no DAC tolerates 2–5 days of ambient temperature shipping (15–30°C) without significant degradation because the solid-state powder lacks water molecules needed for rapid hydrolysis. However, each temperature excursion consumes part of the overall stability budget. Reputable suppliers use cold packs and insulated packaging to minimize thermal exposure, and vials should be transferred to −20°C storage immediately upon arrival.

Using degraded CJC-1295 no DAC introduces uncontrolled variance in peptide concentration and produces inactive fragments that can interfere with receptor assays. Degradation doesn’t render the solution toxic, but it compromises experimental reproducibility — dose-response curves become unreliable, and inter-study comparisons become meaningless. For research demanding precision, discard vials that exceed storage windows regardless of remaining volume.

CJC-1295 no DAC and Sermorelin have nearly identical stability profiles because CJC-1295 no DAC is a modified version of Sermorelin (also known as modified GRF 1-29) with four amino acid substitutions that confer protease resistance. Both maintain 6–12 months shelf life as lyophilised powder at −20°C and 28 days post-reconstitution at 2–8°C. The primary difference is plasma half-life and receptor binding kinetics, not storage stability.

Yes, subdividing lyophilised powder into multiple smaller vials immediately upon receipt allows each aliquot to experience only one freeze-thaw cycle, which significantly reduces cumulative degradation. Use aseptic technique in a laminar flow hood and sterile vials with intact seals. This approach is particularly valuable for long-term studies where a single large vial would be accessed dozens of times over months.

The three most common storage errors are: storing reconstituted peptide at room temperature instead of 2–8°C (causes exponential degradation within hours), using frost-free freezers for lyophilised powder (warming cycles during defrost accelerate solid-state hydrolysis), and injecting air into the vial during reconstitution (introduces oxygen that accelerates oxidative damage). Each error compounds over time and explains most unexplained potency loss in research protocols.

CJC-1295 no DAC is available for research purposes through suppliers like Real Peptides without requiring a prescription, as it is synthesized and sold for laboratory research use under guidelines that distinguish research-grade compounds from pharmaceutical products intended for human therapeutic use. Research-grade peptides are not FDA-approved drugs and are supplied with documentation specifying ‘for research use only’ to maintain regulatory distinction.

Visual inspection provides limited information — clear solutions can still be significantly degraded. The only definitive verification method is third-party HPLC (high-performance liquid chromatography) with UV detection, which quantifies peptide concentration and identifies degradation fragments. Most research labs lack on-site HPLC access, which is why strict adherence to storage protocols (temperature logs, 28-day post-reconstitution limits, minimizing freeze-thaw cycles) is the practical standard for maintaining known potency throughout experimental timelines.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA